SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of

FDMTSLNSLNCF

Related stories